Efficacy of Naloxone in Conjunction with Non-Invasive Ventilation in Managing Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Type II Respiratory Failure

The focus of this research was to investigate the efficacy of using naloxone in conjunction with non-invasive ventilation for managing type II respiratory failure in acute exacerbations of chronic obstructive pulmonary disease. The scope of this retrospective study encompassed the admission of 50 individuals with acute exacerbation of chronic obstructive pulmonary disease and type II respiratory failure to our hospital between January 2019 and December 2022. 25 patients were assigned to both the control group and the observation group. The former was subjected to non-invasive ventilation, whereas the latter received a combination of naloxone and non-invasive ventilation. Comparison was made between the two groups in terms of clinical efficacy, alterations in clinical symptoms, blood gas analysis, and follow-up. The total effective rate for the observation group reached 96.00 %, markedly exceeding the 68.00 % achieved in the control group, with a remarkable variance between the two (p<0.05). Post-treatment, the observation group displayed notable enhancements in respiratory rate, dyspnea score, heart rate, and other parameters, with more evident improvements compared to the control group (p<0.05). Additionally, there were marked enhancements in blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, and oxygen saturation) observed in the observation group, surpassing the improvements in the control group (p<0.05). Both groups encountered adverse effects such as dry mouth, nausea, stomach bloating, and restlessness, yet there was no noteworthy distinction in the comprehensive occurrence of unfavorable reactions between the groups (p>0.05). The conjunction of naloxone and non-invasive ventilation significantly ameliorated the clinical effectiveness of patients dealing with acute chronic obstructive pulmonary disease exacerbations and type II respiratory failure, relieving symptoms and enhancing oxygenation status, resulting in improved long-term results. Although this treatment regimen indicates a level of safety and viability, further research and extensive randomized controlled trials are required to authenticate its long-term effectiveness and safety.